# Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections

> **NCT06660641** · NA · COMPLETED · sponsor: **Rigshospitalet, Denmark** · enrollment: 61 (actual)

## Conditions studied

- Catheter Related Blood Stream Infections
- Intestinal Failure

## Interventions

- **DEVICE:** TaurolockTMHep100
- **DEVICE:** 0.9 % saline

## Key facts

- **NCT ID:** NCT06660641
- **Lead sponsor:** Rigshospitalet, Denmark
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-03
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2024-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06660641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06660641, "Clinical Trial Comparing TaurolockTMHep100 (Taurolidine 1.35%) and 0.9% Saline As Prevention of Recurrent Catheter-related Bloodstream Infections". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06660641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*